Cost-Effectiveness Analysis of Axicabtagene Ciloleucel vs. Tisagenlecleucel for the Management of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Spain.

Bastos-Oreiro, Mariana; de Las Heras, Ana; Presa, María; Casado, Miguel A; Pardo, Carlos; Martín-Escudero, Victoria; Sureda, Anna

Bastos-Oreiro, Mariana; de Las Heras, Ana; Presa, María; Casado, Miguel A; Pardo, Carlos; Martín-Escudero, Victoria; Sureda, Anna.

Afiliação

Bastos-Oreiro M; Hematology Department, Gregorio Marañón Health Institute, 28007 Madrid, Spain.
de Las Heras A; Health Economics Department, Pharmacoeconomics & Outcomes Research Iberia (PORIB), 28224 Madrid, Spain.
Presa M; Health Economics Department, Pharmacoeconomics & Outcomes Research Iberia (PORIB), 28224 Madrid, Spain.
Casado MA; Health Economics Department, Pharmacoeconomics & Outcomes Research Iberia (PORIB), 28224 Madrid, Spain.
Pardo C; Market Access, Reimbursement & Health Economics and Outcomes Research Department, Gilead Sciences, 28033 Madrid, Spain.
Martín-Escudero V; Market Access, Reimbursement & Health Economics and Outcomes Research Department, Gilead Sciences, 28033 Madrid, Spain.
Sureda A; Hematology Department, Institut Català d'Oncologia-Hospitalet, IDIBELL, Universitat de Barcelona, 08908 Barcelona, Spain.

Cancers (Basel) ; 14(3)2022 Jan 21.

Article em En | MEDLINE | ID: mdl-35158805

Palavras-chave

axicabtagene ciloleucel; cost-effectiveness analysis; cost-utility analysis; diffuse large B-cell lymphoma; tisagenlecleucel

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Temas: ECOS / Financiamentos_gastos Bases de dados: MEDLINE Tipo de estudo: Health_economic_evaluation Aspecto: Patient_preference Idioma: En Revista: Cancers (Basel) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Espanha

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google